Likewise, Stalhammar et al. (29) demonstrated that tumor subtyping by a combination of ER, PR, Ki67, and HER2 manual scores was prognostically and predictively inferior when compared to DIA of corresponding biomarkers and concluded that DIA is a robust, reproducible and less time-consuming alternative to the manual scoring in BC. The gene discussed is MKI67; the disease is neoplasm.